INMB Q2 2018 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$6M

Net Income

-$6M

EPS (Diluted)

$-0.55

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$817,847

Free Cash Flow

-$817,847

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$18M

Total Liabilities

$195,334

Stockholders' Equity

$18M

Cash & Equivalents

$1M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$6M	-$165,000	-3641.8%
Net Income	-$6M	-$165,000	-3641.8%